Induction of Acute Ischemic Stroke in Mice Using the Distal Middle Artery Occlusion Technique
December 15th, 2023
3.6K views
Here, we present a protocol to establish a distal middle cerebral artery occlusion (dMCAO) model through transcranial electrocoagulation in C57BL/6J mice and evaluate the subsequent neurological behavior and histopathological features.
Overview
This study presents a detailed protocol for establishing a distal middle cerebral artery occlusion (dMCAO) model in C57BL/6J mice using transcranial electrocoagulation. It focuses on evaluating the resulting neurological behaviors and histopathological features observed post-occlusion.
Key Study Components
Area of Science
- Neurological behavior assessment
- Histopathological analysis
- Ischemic stroke modeling
Background
- The medial cerebral artery (MCA) is key in ischemic strokes in humans.
- Various MCA occlusion methods exist, but dMCAO offers advantages in terms of surgical invasiveness and survival rates.
- The model is beneficial for exploring long-term functional recovery.
Purpose of Study
- To generate a reliable experimental ischemic stroke model in rodents.
- To assess behavioral outcomes and histopathological changes post-stroke.
- To utilize the model for future studies on cognition impairment.
Methods Used
- Transcranial electrocoagulation was employed to induce dMCAO.
- C57BL/6J mice were used to study neurological changes following occlusion.
- Behavioral tests such as grip strength, pole test, adhesive removal, and cylinder test were utilized.
- Histological examination of brain tissue was conducted post-behavioral assessments.
Main Results
- Mice exhibited significant reductions in grip strength and increased descent times on various behavioral tests.
- Histological analysis showed disordered neuron arrangements and reduced cell density in the peri-infarct area.
Conclusions
- The study establishes a robust dMCAO model with high reproducibility for stroke research.
- This methodology will enhance understanding of structural and behavioral outcomes after ischemic stroke.
- Future applications could focus on cognitive impairments in post-stroke recovery.
Frequently Asked Questions
What are the advantages of using the dMCAO model?
The dMCAO model offers decreased surgical invasiveness, smaller infarction sizes, and improved survival rates, making it suitable for long-term studies.
How is the MCA occlusion implemented in this study?
The MCA occlusion is achieved via transcranial electrocoagulation, with careful monitoring of blood flow and subsequent closure of the surgical site.
What types of outcomes are measured in this research?
The study measures neurological behaviors through various tests and evaluates histopathological changes in the brain tissue after the occlusion.
How can this method be adapted for future research?
This methodology can be adapted for investigating various cognitive and sensory deficits after ischemic strokes using different behavioral paradigms.
What are the key limitations of this study?
Limitations include the model being solely conducted in rodents, which may not entirely replicate human pathology, and the focus on acute outcomes post-stroke.
What insights does this study offer about stroke recovery?
The findings provide insights into the structural and behavioral changes that occur after ischemic stroke, paving the way for future investigations into recovery mechanisms.
Executive Industry Relevance
The distal middle cerebral artery occlusion (dMCAO) mouse model provides a reproducible and translationally relevant system for interrogating the pathophysiology of ischemic stroke and evaluating candidate interventions. Its moderate, cortex-restricted infarct and high survival rate enable robust assessment of neurological and histopathological outcomes, supporting predictive confidence in early-stage target validation. This model is strategically positioned for portfolio triage and mechanistic de-risking in preclinical cerebrovascular research.
Strategic Applications in Biopharma R&D
Early Discovery & Target Validation
- Enables interrogation of therapeutic hypotheses targeting post-stroke neuroprotection and repair.
- Supports biological de-risking by modeling neuron degeneration and glial activation in a controlled system.
- Facilitates functional target validation through quantifiable behavioral and histological endpoints.
- Provides predictive confidence for advancing neurovascular targets in the discovery pipeline.
Screening & Assay Development
- Establishes a validated in vivo system for screening neuroprotective compounds and interventions.
- Delivers standardized, reproducible behavioral assays such as grip strength, pole, adhesive, and cylinder tests.
- Enables quantitative measurement of infarct size and neuronal loss for comparative compound evaluation.
- Supports assay scalability and platform reuse across neurovascular research programs.
Translational & Preclinical Research
- Aligns with disease-relevant mechanisms observed in human cortical stroke.
- Provides continuity from early discovery through preclinical validation of functional and histopathological outcomes.
- Enables risk-adjusted advancement decisions based on translationally relevant behavioral and cellular readouts.
- Supports future studies on cognitive impairment and long-term recovery post-stroke.
Pipeline & Workflow Integration
The dMCAO model integrates into the discovery-to-preclinical continuum, bridging early mechanistic studies with translational efficacy assessments for stroke therapeutics.
- Discovery Biology: Facilitates hypothesis testing and pathway clarification for neuroprotection and repair.
- Screening: Provides reproducible, quantitative behavioral and histological outputs for compound triage.
- Analytics: Enables statistical comparison of neurological deficits and infarct metrics across experimental groups.
- Translational Research: Aligns preclinical findings with human stroke pathology for biomarker and endpoint validation.
- Enterprise Reuse: Serves as a standardized platform for cross-program evaluation of neurovascular interventions.
Operational & Enterprise Impact
- Scientific Value: Increases predictive confidence and reduces mechanistic ambiguity in stroke target validation.
- Operational Value: Delivers standardized, reproducible, and scalable in vivo workflows for neurovascular research.
- Strategic Value: Supports informed go/no-go decisions and capital-efficient portfolio advancement.
- Portfolio Impact: Enables risk-adjusted prioritization of neuroprotective and regenerative candidates.
Implementation Considerations
- Requires expertise in microsurgical techniques and rodent behavioral phenotyping.
- Necessitates access to specialized instrumentation for electrocoagulation and behavioral testing.
- Demands rigorous cross-team standardization of surgical and analytical protocols.
- Adaptation may be needed for different mouse strains or comorbidity models.
- Model is limited to cortical infarcts and may not capture all aspects of human stroke heterogeneity.
Biopharma FAQs
Why does null hypothesis testing matter for grip strength assessment?
Null hypothesis testing in grip strength assays enables objective evaluation of motor deficits post-dMCAO, supporting robust target validation and minimizing false-positive efficacy claims in early discovery.
How does independent variable isolation in electrocoagulation fit the discovery pipeline?
Isolating the occlusion site via transcranial electrocoagulation ensures that observed neurological and histopathological changes are attributable to targeted vascular disruption, enhancing mechanistic clarity for discovery-stage studies.
What do quantitative behavioral test measurements enable in preclinical stroke models?
Quantitative outputs from grip strength, pole, adhesive, and cylinder tests provide reproducible endpoints for comparing intervention efficacy and enable data-driven advancement decisions in preclinical pipelines.
Why are replication requirements critical for cross-functional behavioral testing?
Replication of behavioral and histological outcomes across cohorts ensures reliability and comparability, facilitating cross-functional collaboration and standardization in multi-site R&D programs.
What statistical analysis capabilities are required before implementing infarct size quantification?
Robust statistical analysis is essential for interpreting TTC-stained infarct size data, enabling teams to distinguish true intervention effects from biological variability and inform portfolio triage decisions.
Chapters in this video
0:00
Introduction
2:19
Distal Middle Artery Occlusion Procedure to Induce Ischemic Stroke in Mice
4:18
Neurological Behavioral Tests in Distal Middle Artery Occluded Mice to Study Ischemic Stroke Outcomes
6:09
Mouse Brain Histology to Study the Pathological Mechanisms of Ischemic Stroke Induced by Distal Middle Artery Occlusion
